Cartesian Therapeutics, Inc.
RNACDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
RNAC Earnings Report
EPS Est: $-0.82 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How RNAC's past catalysts played out
Decartes-08
Myasthaenia Gravis
Descartes-08
Systemic Lupus Erythematosus (SLE)
Descartes 11
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Decartes-08 | Phase 3 | Myasthaenia Gravis | - | - |
Descartes-08 | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
Descartes 11 | Phase 2 | Multiple Myeloma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cartesian Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cartesian Therapeutics, Inc.'s (RNAC) pipeline across Phase 3, Phase 2. Its lead program is Decartes-08 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cartesian Therapeutics, Inc.'s next FDA catalyst?→
Cartesian Therapeutics, Inc.'s (RNAC) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RNAC biotech catalysts?→
Add RNAC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cartesian Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.